The number of US citizens that’s seeking the help of a Xarelto lawyer to bring their cases in court is growing to unprecedented levels. Since New Year’s eve, more than 400 Xarelto lawsuits have been added to the already large amount of other cases that form the Xarelto Multidistrict Litigation (MDL number 2592) in New Orleans. The large Xarelto MDL now includes almost 3,000 Xarelto injury lawsuits that will be held before U.S. District Honourable Judge Eldon E. Fallon, in addition to the 500 cases of the Philadelphia, PA Xarelto Mass Tort.
Plaintiffs and their Xarelto Attorneys accuse Janssen Pharmaceuticals and Bayer AG of not adequately warning them about the risks associated with the use of the blood thinner. Xarelto side effects did, in fact, include severe bleedings that in some circumstances even led patients to death. As no Xarelto antidote has ever been approved, even the smallest Xarelto uncontrollable bleeding accident can prove to be fatal, and for this reason, many families are now filing Xarelto bleeding lawsuits to ask for proper compensation.
Plaintiffs’ claims are very similar to those alleged in the previously settled Pradaxa litigation. Patients blame the pharmaceutical companies of holding precious information about the drug’s purported safety, as well as being negligent in warning the public of its dangerous side effects. Pradaxa was manufactured by Boehringer Ingelheim in 2010, just one year before Xarelto was released to the market. Similarly to Xarelto lawsuits, Pradaxa lawsuits reached a total of over 4,000 cases, and the pharmaceutical company agreed to pay $650 million to settle down the accusations. Xarelto lawyers hope for a similar solution and are encouraging patients who suffered any type of harm caused by Xarelto uncontrollable bleedings, to file a Xarelto lawsuit before the time limit is over.
This large number of litigations led Xarelto Attorneys to be very positive about the potential outcome of this trial. The number of cases increased from 2,400 to 2,800 in just one month, with an almost +20% net growth that will probably keep increasing in the upcoming months.
Article written by: Dr. Claudio Butticè, Pharm.D.
Published: 2016/02/01
